ArticleESMO real world data and digital oncology2025
Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach.
Article in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care.ESMO real world data and digital oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent advancements in cancer treatment have shifted the paradigm from chemotherapy to targeted therapies and immunotherapies, proving effective even in early-stage cancers. Regulatory agencies like the Food and Drug Administration, European Medicines Agency, and Italian Agency for Drugs have approved several targeted therapies for specific genetic mutations, significantly improving outcomes for several diseases. These advancements highlight the importance of identifying molecular targets, even in historically difficult-to-treat cancers. Materials and methods: A retrospective observational study was conducted at the University of Campania "Luigi Vanvitelli" from January 2015 to January 2022, involving 83 adult patients with solid tumors. Patients received off-label drugs at no cost. The study analyzed treatment and pathology data, focusing on progression-free survival (PFS) and overall survival (OS), using Kaplan-Meier estimates and the log-rank test for statistical analysis. Results: Patients averaged 63 years old, with a slight male majority. Off-label drugs were primarily requested for upper gastrointestinal cancers (42%) and colorectal carcinoma (21%). The most common molecular testing method was next-generation sequencing (NGS). Immunotherapy was the predominant treatment (67%), followed by targeted therapy and chemotherapy. The median PFS was 3.4 months [95% confidence interval (CI) 2.0-4.5 months], and the median OS was 10 months (95% CI 7.5-12.2 months). Early-line off-label treatment showed a trend toward longer PFS compared with later lines. Conclusion: Early access to off-label drugs, particularly for patients with specific genetic alterations, can improve outcomes. The study underscores the importance of molecular tumor boards and multidisciplinary collaboration in selecting off-label treatments. Despite regulatory and ethical challenges, off-label drug use offers significant therapeutic opportunities, necessitating well-designed clinical trials and registries to better understand their efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.